Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | PHASE1 | COMPLETED | 36 | — | — | Oct 1, 2006 | Jun 1, 2007 | Sep 24, 2009 | 4 | Canada |
| Name | Type | Description |
|---|---|---|
| VCH-759 (BCH-27759) | DRUG | - |
Inclusion Criteria: * 18 to 60 years of age * Body mass index (BMI) ≤ 30 * No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3 * Subject's liver disease is stable (i.e., stable ALT and AST) * Serologic evidence of chronic hepatitis C-infection (anti-HCV in serum) ...